---
title: "Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296368941.md"
description: "Jiangsu Hengrui Medicine Co. Ltd. launched an A-share buyback plan ranging from RMB 1 billion to RMB 2 billion via centralized price bidding. The repurchased shares will fund an employee stock ownership scheme, with a maximum purchase price capped at RMB 81.78 per share. The program is scheduled to run for up to 12 months starting August 19, 2026, targeting the acquisition of approximately 12.2 million to 24.5 million shares."
datetime: "2026-08-19T14:15:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296368941.md)
  - [en](https://longbridge.com/en/news/296368941.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296368941.md)
generator: "portal-rs"
---

# Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78

-   Jiangsu Hengrui launched an A-share buyback plan of RMB 1-2 billion via centralized price bidding. \* Repurchases to fund an A-share employee stock ownership scheme; maximum price set at RMB 81.78 per share. \* Program runs up to 12 months from Aug. 19, 2026; estimated 12,227,900-24,455,900 shares, or 0.18%-0.37% of share capital. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12291176), on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [BOCOM International Cuts HENGRUI PHARMA  TP to HKD57, Lowers Earnings Forecasts; Valuation Reasonable, Rated Neutral](https://longbridge.com/en/news/296864544.md)
- [Panatlantica sets BRL 4.91 per unit distribution for OR6 shares, BRL 3.49 for PR3](https://longbridge.com/en/news/296523642.md)
- [NOSA: Q2 2026 saw 81% sales growth, improved EBITDA, and major market expansions](https://longbridge.com/en/news/296576810.md)
- [Jiangsu Hengrui files HKEX next-day disclosure return reporting share repurchase at RMB 52.96](https://longbridge.com/en/news/294665198.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**